George Cindy, Mogueo Amelie, Okpechi Ikechi, Echouffo-Tcheugui Justin B, Kengne Andre Pascal
Non-Communicable Disease Research Unit, South African Medical Research Council, Parow, Cape Town, South Africa.
Department of Management, Assessment and Health Policy, School of Public Health, The University of Montreal, Montreal, Canada.
BMJ Glob Health. 2017 May 29;2(2):e000256. doi: 10.1136/bmjgh-2016-000256. eCollection 2017.
Chronic kidney disease (CKD) is fast becoming a major public health issue, disproportionately burdening low-income to middle-income countries, where detection rates remain low. We critically assessed the extant literature on CKD screening in low-income to middle-income countries. We performed a PubMed search, up to September 2016, for studies on CKD screening in low-income to middle-income countries. Relevant studies were summarised through key questions derived from the Wilson and Jungner criteria. We found that low-income to middle-income countries are ill-equipped to deal with the devastating consequences of CKD, particularly the late stages of the disease. There are acceptable and relatively simple tools that can aid CKD screening in these countries. Screening should primarily include high-risk individuals (those with hypertension, type 2 diabetes, HIV infection or aged >60 years), but also extend to those with suboptimal levels of risk (eg, prediabetes and prehypertension). Since screening for hypertension, type 2 diabetes and HIV infection is already included in clinical practice guidelines in resource-poor settings, it is conceivable to couple this with simple CKD screening tests. Effective implementation of CKD screening remains a challenge, and the cost-effectiveness of such an undertaking largely remains to be explored. In conclusion, for many compelling reasons, screening for CKD should be a policy priority in low-income to middle-income countries, as early intervention is likely to be effective in reducing the high burden of morbidity and mortality from CKD. This will help health systems to achieve cost-effective prevention.
慢性肾脏病(CKD)正迅速成为一个重大的公共卫生问题,在低收入至中等收入国家造成了不成比例的负担,而这些国家的检出率仍然很低。我们严格评估了关于低收入至中等收入国家CKD筛查的现有文献。我们在PubMed上进行了检索,截至2016年9月,查找关于低收入至中等收入国家CKD筛查的研究。通过从威尔逊和荣格纳标准衍生出的关键问题对相关研究进行了总结。我们发现,低收入至中等收入国家没有足够的能力应对CKD的灾难性后果,尤其是疾病的晚期。有一些可接受且相对简单的工具可协助这些国家进行CKD筛查。筛查应主要包括高危个体(患有高血压、2型糖尿病、HIV感染或年龄>60岁者),但也应扩展到风险水平次优的个体(如糖尿病前期和高血压前期)。由于在资源匮乏地区,高血压、2型糖尿病和HIV感染的筛查已纳入临床实践指南,因此可以将其与简单的CKD筛查测试相结合。CKD筛查的有效实施仍然是一项挑战,而且这项工作的成本效益在很大程度上仍有待探索。总之,出于许多令人信服的原因,CKD筛查应成为低收入至中等收入国家的政策优先事项,因为早期干预可能有效地减轻CKD的高发病率和死亡率负担。这将有助于卫生系统实现具有成本效益的预防。